All In Biotech

Drug Trial Radar · NCT04148963

A Study of Staccato Loxapine (ADASUVE®) for Inhalation

A Multi-center, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Staccato Loxapine (ADASUVE®) for Inhalation in Acutely Agitated Patients With Schizophrenia or Bipolar Disorder

Last checked: Nov 20, 2026Latest source record: Nov 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

150

Planned (sponsor's estimate)

Start

Dec 1, 2019

Primary completion

May 1, 2020

Study completion Aug 1, 2020

Sponsor

Lead sponsor
Lee's Pharmaceutical LimitedIndustry
Sponsor type
Industry
First posted
Nov 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in schizophrenic or bipolar disorder patients.

Conditions

  • Psychomotor Agitation
  • Schizophrenia
  • Bipolar Disorder

Interventions

  • Inhaled loxapineDrug

    Inhaled Loxapine 9.1 mg, may repeat x 1 or 2 after 2 hours

  • Inhaled placeboDrug

    Inhaled placebo, may repeat x 1 or 2 after 2 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in PANSS-EC From BaselineTime frame: Time Frame: Baseline and 2 hours

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.